Interleukin-1β, Calcium-Sensing Receptor, and Urokinase Gene Polymorphisms in Korean Patients with Urolithiasis by Kim, Joon-Young et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 340 Korean J Urol 2011;52:340-344
www.kjurology.org
DOI:10.4111/kju.2011.52.5.340
Urolithiasis
Interleukin-1β, Calcium-Sensing Receptor, and Urokinase Gene 
Polymorphisms in Korean Patients with Urolithiasis
Joon-Young Kim, Young-Sun Kim, In-Ho Jang, Jae-Dong Jung, Tae-Hyoung Kim, Hye-Ryun Kim
1
Departments of Urology and 
1Laboratory Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
Purpose: There are various causes of ureter calculi, and genetic factors are known to 
play a role. Interleukin-1β (IL-1β) and calcium-sensing receptor (CaSR) genes are re-
lated to hypercalciuria, and urokinase is related to the formation of calcium oxalate 
stones. This study investigated polymorphisms in IL-1β, CaSR, and urokinase in pa-
tients with urolithiasis and healthy controls.
Materials and Methods: Urolithiasis patients treated at Chung-Ang University 
Hospital were enrolled from January 2007 to December 2008. The control group of vol-
unteers displayed normal urinalysis findings in the health screening, no stones identi-
fied by ultrasonography, and no history of urolithiasis. DNA extracted from peripheral 
blood was analyzed by the polymerase chain reaction. Patients were genetically 
screened for mutations in IL-1β (484 urolithiasis patients, 208 controls), CaSR (433 
urolithiasis patients, 197 controls), and urokinase (370 urolithiasis patients, 167 con-
trols). Stone metabolic study was done to see the differences between the metabolic fac-
tors and to discern normal genes from polymorphic genes.
Results: According to the genotype frequency and allele frequency analysis, there were 
no statistically significant differences between IL-1β, CaSR, and urokinase genes. Also, 
the analysis between genotypes and metabolic factors did not show statistically sig-
nificant differences between the three genes. 
Conclusions: In Korean urolithiasis patients, IL-1β, CaSR, and urokinase gene poly-
morphisms do not differ from those of healthy individuals. A larger-scale study is need-
ed to confirm the need for other genetic markers of urolithiasis.
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INTRODUCTION
Various causes determine the formation of ureter calculi, 
and genetic factors are known to play a role. Studies have 
tried to identify genes related to ureter calculi in an effort 
to clarify the cause of urolithiasis and to advance the diag-
nosis and treatment of urolithiasis [1,2]. In other studies, 
the use of single-nucleotide polymorphisms (SNPs) asso-
ciated with genetic diseases has been fruitful in identifying 
candidate disease genes. Recent genetic advances in ur-
olithiasis indicate the potential of a new approach towards 
the gene polymorphism [3-7]. 
　Interleukin-1β (IL-1β) is a potent proinflammatory agent 
that can induce bone resorption, osteoclast formation, and 
hypercalciuria. The calcium-sensing receptor (CaSR) reg-
ulates cellular calcium homeostasis and controls para-
thyroid hormone secretion that is controlled by urinary cal-
cium absorption. Urokinase functions to degrade the or-
ganic matrix of nascent urinary stones, preventing their 
full formation and growth. Hypothesizing that these genes 
might be crucial in urolithiasis, the present study exam-
ined gene polymorphisms in IL-1β, CaSR, and urokinase 
in Korean urolithiasis patients and healthy controls. Korean J Urol 2011;52:340-344
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FIG. 1. Representative agarose gel elec-
trophoresis illustrating the restriction
fragment length polymorphism prod-
ucts for the polymorphisms of the three 
examined genes. IL-1β: T allele cut gen-
erated 155-bp fragments and the C al-
lele cut generated 88- and 67-bp frag-
ments. CaSR: T allele cut generated 
218-bp fragments and the t allele cut 
generated 198-bp fragments. Urokina-
se: T allele cut generated 185-bp frag-
ments and the C allele cut generated 
210-bp fragments.
MATERIALS AND METHODS
1. Subjects
From January 2007 to December 2008, patients who had 
a confirmed diagnosis after a radiological exam, such as 
computed tomography, intravenous pyelography, or kid-
ney ultrasonography, and who were treated for urolithiasis 
with open surgery, ureterorenoscopic lithotripsy, extra-
corporeal shock wave lithotripsy, or conservative treatment 
at Chung-Ang University Hospital were involved in this 
study. Informed consent for genetic testing was given by 
those who agreed to participate. The control group con-
sisted of patients displaying normal urinalysis findings 
from the health screening, absence of stones as identified 
by ultrasonography, and no history of urolithiasis. Genetic 
testing was performed as described below to detect poly-
morphisms in IL-1β (484 urolithiasis patients, 208 con-
trols), CaSR (433 urolithiasis patients, 197 controls), and 
urokinase (370 urolithiasis patients, 167 controls). The 
study protocol was approved by the Chung-Ang University 
Institutional Review Board.
2. Methods
1) Genomic DNA isolation: Genomic DNA was isolated from 
peripheral blood leukocytes in EDTA-containing tubes. All 
processes were done according to the manufacturer’s in-
structions by use of the Wizard Genomic DNA Purification 
Kit (Promega, Madison, WI, USA).
2) Amplification and confirmation of each mutation (Fig. 1)
　(1) IL-1β T/C: The extracted DNA was amplified by poly-
merase chain reaction (PCR) with the forward primer 5‘-G 
CCTGAACCCTGCATACCGT-3' and the reverse primer 
5’-GCCAATAGCCCTCCCTGTCT-3'. PCR procedures were 
carried out in a total volume of 20 μl containing genomic 
DNA, each primer, and Taq DNA polymerase. PCR amplifi-
cation was performed in a programmable thermal cycler 
GeneAmp PCR system 9700 (Applied Biosystems, Foster 
City, CA, USA). The cycling conditions for IL-1β T/C poly-
morphism were 1 cycle at 95
oC for 5 minutes; 35 cycles at 
94
oC for 30 seconds, 56
oC for 30 seconds, and 72
oC for 30 sec-
onds; and a final cycle at 72
oC for 10 minutes. Then, 5 μl 
of the product was loaded onto 3% agarose gel plates con-
taining ethidium bromide for electrophoresis. The 155-bp 
PCR product was mixed with 10 U/μl of AvaI restriction en-
zyme (Enzynomics, Daejeon, Korea) and the restriction 
buffer according to the manufacturer’s instructions. The 
thymine in the wild-type sequence is replaced by cytosine 
as the polymorphic mutation, generating a recognition site 
for AvaI. The resulting digestion generates 88-bp and 68-bp 
fragments.
　(2) CaSR: A986S: Primers were designed to amplify the 
region containing the A986S polymorphism (forward pri-
mer 5‘-CTTTGATGAGCCTCAGAAGAGC-3' and reverse 
primer 5’-ACAACTCTTCAGGGTCCTCC-3'). The PCR cy-
cling condition for CaSR gene polymorphism was 1 cycle at 
95
oC for 5 minutes; 35 cycles at 94
oC for 30 seconds, 58
oC 
for 30 seconds, and 72
oC for 45 seconds; and a final cycle 
at 72
oC for 7 minutes. The 218-bp PCR product was mixed 
with 20 U/μl of SacI restriction enzyme (Enzynomics) and 
the restriction buffer according to the manufacturer’s in-
structions. SacI would recognize a recognition site in the 
mutant allele producing fragments of 218-bp and 198-bp.
　(3) Urokinase 3’ untranslated region (UTR): The extracted 
DNA was PCR-amplified by using the forward primer 5‘-C 
CGCAGTCACACCAAGGAAGAG-3' and the reverse pri-
mer 5’-GCCTGAGGGTAAAGCTATTGTCGTGCAC-3'. The 
PCR cycling condition for the urokinase 3’ UTR polymorphism 
was 1 cycle at 94
oC for 5 minutes; 35 cycles at 94
oC for 30 sec-
onds, 58
oC for 30 seconds, and 72
oC for 40 seconds; and a 
final cycle at 72
oC for 7 minutes. The 210-bp PCR product 
was mixed with 20 U/μl of ApaL1 restriction enzyme and 
the restriction buffer according to the manufacturer’s in-
structions. Polymorphism would generate an enzyme recog-
nition site, and digestion would produce fragments of 185- 
bp and 25-bp.
3) Stone metabolic study: IL-1β, CaSR, and urokinase poly-
morphisms were determined in the urolithiasis patients. 
Each genotype was classified into groups and the average 
sodium, calcium, citrate, and oxalate concentrations in 
urine collected for over 24 hours were determined, as was 
the 24-hour urine volume.
4) Statistics: The chi-square test was used for the statistical 
analysis of gene frequency and allele frequency, and one- 
way ANOVA was used for the statistical analysis of meta-
bolic factors between the three genes. SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA) was used, with p-values less than Korean J Urol 2011;52:340-344
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TABLE 1. Gene and allele frequencies of interleukin-1β in ur-
olithiasis patients and healthy controls
 
Urolithiasis patients (%) 
(n=484)
Control (%)
(n=208)
p-value
Gene frequency
　CC   61 (12.6)   33 (15.9) ＞0.05
　CT 282 (58.3) 123 (59.1) ＞0.05
　TT 141 (29.1) 52 (25) ＞0.05
Allele frequency
　T 564 (58.3) 227 (54.6) ＞0.05
　C 404 (41.7) 189 (45.4) ＞0.05
TABLE 2. Gene and allele frequencies of calcium-sensing receptor
gene in urolithiasis patients and healthy controls
Urolithiasis patients (%) 
(n=433)
Control (%)
(n=197)
p-value
Gene frequency
　TT 415 (95.9) 191 (97) ＞0.05
　Tt 18 (4.1)  6 (3) ＞0.05
Allele frequency
　T 848 (98) 388 (98.5) ＞0.05
　t 18 (2)   6 (1.5) ＞0.05
TABLE 3. Gene and allele frequencies of urokinase gene in ur-
olithiasis patients and healthy controls
Urolithiasis patients 
(%) (n=370)
Control (%)
(n=167)
p-value
Gene frequency
　CT 212 (57.3) 104 (62.3) ＞0.05
　TT 158 (42.7)   63 (37.7) ＞0.05
Allele frequency
　T 528 (71.3) 230 (68.9) ＞0.05
　C 212 (28.7) 104 (31.1) ＞0.05
TABLE 6. Laboratory findings in urolithiasis patients according 
to urokinase gene variation
Category
Urokinase
p-value
CT TT
uNa 276.4±377.9 203.2±108.5 NS
uCa 177.7±121.5 197.6±118.8 NS
Citrate 273.1±196.4 335.3±243.1 NS
Oxalate 37.8±17.7 37.1±19.2 NS
Urine vol 2,500.0±2,751.8 2,751.8±1,645.5 NS
NS: not significant. Normal range: urine Na (0-200 mEq), urine
Ca (0-250 mg), citrate (＞320 mg), oxalate (0-45 mg), urine volume
(＞2,000 ml). uNa: sodium in urine. uCa: calcium in urine
TABLE 5. Laboratory findings in urolithiasis patients according 
to calcium-sensing receptor gene variation
Category
CaSR
p-value
TT Tt
uNa 215.9±180.5 134.2±41.8 NS
uCa 190.3±112.0 138.6±84.0 NS
Citrate 334.9±222.9 276.7±163.1 NS
Oxalate 37.9±20.8 22.4±15.0 NS
Urine vol 2,675.0±1,542.5 1,670±887.0 NS
NS: not significant. Normal range: urine Na (0-200 mEq), urine
Ca (0-250 mg), citrate (＞320 mg), oxalate (0-45 mg), urine volume
(＞2,000 ml). uNa: sodium in urine. uCa: calcium in urine
TABLE 4. Laboratory findings in urolithiasis patients according to interleukin-1β gene variation 
Category
Interleukin-1β
p-value
CC CT TT
uNa 248.1±387.6 195.05±98.1 218.6±109.9 NS
uCa 154.3±102.6 194.9±111.7 196.3±196.2 NS
Citrate 278.2±186.8 358.1±269.4 333.8±210.0 NS
Oxalate 37.9±20.5 37.9±20.5 37.8±20.3 NS
Urine vol 2,615.7±1,347.2 2,615.6±1,347.3 2,931.1±1,721.7 NS
NS: not significant. Normal range: urine Na (0-200 mEq), urine Ca (0-250 mg), citrate (＞320 mg), oxalate (0-45 mg), urine volume
(＞2,000 ml). uNa: sodium in urine. uCa: calcium in urine
0.05 considered significant. 
RESULTS
1. Genotype frequency
In urolithiasis patients, the C/C, C/T, and T/T IL-1β gene 
polymorphisms were detected in 61 (12.6%), 282 (58.3%), 
and 141 patients (29.1%), respectively. The respective pro-
portions in the normal controls were 33 (15.9%), 123 
(59.1%), and 52 patients (25%) (Table 1). In urolithiasis pa-
tients, the T/T and T/t CaSR gene polymorphisms were 
detected in 415 (95.9%) and 18 patients (4.1%), respec-
tively. The respective proportions in the normal controls 
were 191 patients (97%) and 6 patients (3%) (Table 2). In 
urolithiasis patients, the C/T and T/T urokinase gene 
polymorphisms were detected in 212 (57.3%) and 158 pa-
tients (42.7%), respectively. The respective proportions in 
the normal controls were 104 (62.3%) and 63 patients 
(37.7%) (Table 3). No statistically significant differences 
were evident between the patient groups and the control Korean J Urol 2011;52:340-344
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groups for any of the genes.
2. Allele frequency
The C and T IL-1β allele frequencies in the 484 urolithiasis 
patients were 404 patients (41.7%) and 564 patients (58.3%), 
respectively. The respective proportions of the 208 control 
patients were 189 patients (45.4%) and 227 patients (54.6%). 
The T and t CaSR allele frequencies in 433 urolithiasis pa-
tients were 848 patients (98%) and 18 patients (2%). The 
respective proportions of the 197 normal controls were 388 
patients (98.5%) and 6 patients (1.5%). The T and C uro-
kinase allele frequencies in the 370 urolithiasis patients 
were 528 patients (71.3%) and 212 patients (28.7%), re-
spectively. The respective proportions in the 167 normal 
controls were 230 patients (68.9%) and 104 patients (31.1%). 
No statistically significant differences were evident be-
tween the patient groups and the control groups for any of 
the genes.
3. Genotyping and laboratory findings
IL-1β, CaSR, and urokinase genotypes of the urolithiasis 
patients (Table 4-6, respectively) were compared with the 
means of laboratory findings. No significant differences 
were apparent. 
DISCUSSION
Genetic factors influence the formation of urinary calculi. 
For example, the formation of urinary calcium stones, uri-
nary calcium and hydroxyl concentrations, crystallization 
growth factors, and inhibitory factors are affected by genet-
ic factors [8]. In addition, calcium oxalate stones have been 
linked to a polygenic defect [2]. Also, there is a report that 
hypercalciuria and urolithiasis are related. However, ge-
netic details of hypercalciuria and urolithiasis patients are 
unclear; thus, it remains unresolved whether one or sev-
eral genes are involved in calculi formation [8].
　For a disease such as urolithiasis, which results from the 
complex interaction of multiple factors, determination of 
SNPs is useful to identify disease-related gene(s). The com-
plete roster of polymorphic markers must be resolved with 
the need to identify 90% or more of the relevant SNPs. SNPs 
differ appreciably with race, although about 30% are com-
mon between all races. Much SNP research has been done 
in other countries, but none in Korea. In the present study, 
we aimed to determine SNPs in Korean patients. 
　IL-1β functions to localize the bone marrow macrophage 
to the site of inflammation, to stimulate differentiation of 
macrophages into osteoclasts by activation around the 
bone, and to cause hypercalciuria [9]. Similar to the present 
results, a study of IL-1β polymorphism conducted in China 
on patients with calcium oxalate stones did not find evi-
dence of a statistically significant association of the poly-
morphism with the patient group [10]. A study in India re-
ported a significantly higher risk for urolithiasis in pa-
tients with a combination of high IL-1β and low IL-1 re-
ceptor antagonist genotypes [11]. This is consistent with 
the aforementioned racial difference in gene polymorphism. 
It seems that research on genetic factors to determine why 
there are low relations between IL-1β and urolithiasis in 
Asians is needed. In the present study, we compared the 
laboratory results of 24-hour collected urinary sodium, cal-
cium, hydroxyl, and citric acid and urine volume according 
to each genotype. No significant differences were revealed. 
CaSR gene inactivation caused by mutations is associated 
with diseases characterized by hypocalciuria and hyper-
calcemia because gene inactivation causes changes in par-
athyroid hormone secretion and calcium reabsorption of 
tubular cells. CaSR gene mutation also seems to be the 
cause of idiopathic hypercalciuria, which is a risk factor for 
calcium renal stone formation and is characterized by an 
increase in calcium excretion even when normal plasma 
calcium ion is maintained [10,12,13]. A study from Brazil 
reported that CaSR polymorphism was overrepresented in 
hypercalciuric stone formers but that urinary calcium ex-
cretion was not associated with polymorphism [14]. Pre-
sently, CaSR gene polymorphism analysis did not reveal 
genotype differences between urolithiasis patients and 
normal controls. When allele frequency was classified into 
T and t, no statistically significant difference was found, 
in agreement with the study of Italian urolithiasis patients 
(although statistical differences in CaSR mutations and 
hypercalciuira were reported) [15]. Likewise, the labo-
ratory results of 24-hour urinary sodium, calcium, hydrox-
yl, and citric acid and urine volume were compared accord-
ing to each genotype, and again no significant differences 
were revealed. Urokinase was originally isolated from hu-
man urine, but is present in several physiological locations, 
such as the bloodstream and the extracellular matrix. The 
primary physiological substrate of the enzyme is plasmi-
nogen, which is an inactive zymogen form of the serine pro-
tease plasmin. It is assumed that urokinase breaks the or-
ganic matrix of nascent urinary stones, preventing their 
complete formation and growth. In a study of urolithiasis 
urokinase gene polymorphism conducted on patients in 
China, T allele carriers had a statistically higher incidence 
of calcium oxalate stones [16]. A study from India also re-
ported a significant difference in the distribution of the uro-
kinase gene C/T polymorphism between patients with 
stones and controls [17]. In the present study, the uro-
kinase gene polymorphism analysis showed no genotype 
differences between urolithiasis patients and normal con-
trols in the prevalence of the C and T alleles, which may 
reflect racial differences. Likewise, there were no statisti-
cally significant differences in urine parameters. 
CONCLUSIONS
Polymorphisms of IL-1β, CaSR, and urokinase did not sig-
nificantly differ in Korean urolithiasis patients from those 
of a control group. A larger-scale study is needed to confirm 
the need for other genetic markers of urolithiasis.Korean J Urol 2011;52:340-344
344 Kim et al
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